Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16388417 | 0.86 | TSHR (0.55) | SLC1A1TSHRCA1CA2CA12 | |
| SCHEMBL3275556 | 0.85 | MME (0.47) | MMECA1CA2FOLH1 | |
| SCHEMBL1419634 | 0.85 | MME (0.47) | MMECA1CA2FOLH1 | |
| SCHEMBL3273833 | 0.85 | MME (0.47) | MMECA1CA2FOLH1 | |
| SCHEMBL19483366 | 0.83 | SLC1A1 (0.49) | SLC1A1TSHRMMECA12CA14 | |
| SCHEMBL19483395 | 0.83 | SLC1A1 (0.49) | SLC1A1TSHRMMECA12CA14 | |
| SCHEMBL28741676 | 0.83 | CA1 (0.52) | SLC1A1TSHRCA1CA2CA12 | |
| SCHEMBL2979680 | 0.81 | MME (0.53) | MMECA1CA2CA14FOLH1 | |
| SCHEMBL526220 | 0.80 | SLC1A1 (0.49) | SLC1A1TSHRCA1CA2CA12 | |
| SCHEMBL9509840 | 0.80 | CA1 (0.62) | SLC1A1TSHRCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483317-A | The preparation method and application of high-purity 3- isobutylglutaric acid dimethyl ester | HUANGGANG LUBAN PHARMACEUTICAL CO LTD | 2019-11-22 | — | — | CN | disclosed |
| EP-2297090-A1 | STEREOSELECTIVE ENZYMATIC SYNTHESIS OF (S) OR (R)-ISO-BUTYL-GLUTARIC ESTER | Teva Pharmaceutical Industries Ltd. (IL) | 2011-03-23 | — | — | EP | disclosed |
| US-20100087525-A1 | STEREOSELECTIVE ENZYMATIC SYNTHESIS OF (S) OR (R)-ISO-BUTYL-GLUTARIC ESTER | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-08 | — | — | US | disclosed |
| WO-2009158343-A1 | STEREOSELECTIVE ENZYMATIC SYNTHESIS OF (S) OR (R)-ISO-BUTYL-GLUTARIC ESTER | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087525-A1 | STEREOSELECTIVE ENZYMATIC SYNTHESIS OF (S) OR (R)-ISO-BUTYL-GLUTARIC ESTER | COASY, HSD17B12, GABRB2 | SLC1A1 487/4885TSHR 3764/4885MME 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.